Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company...
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 11950
- Registration Number
- NCT04796896
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸West Houston Clinical Research - Hunt, Houston, Texas, United States
🇺🇸Clinical Research Institute, Inc - CRN - PPDS, Minneapolis, Minnesota, United States
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 4331
- Registration Number
- NCT04649151
- Locations
- 🇺🇸
Velocity Clinical Research - Banning, Banning, California, United States
🇺🇸Paradigm Clinical Research, La Mesa, California, United States
🇺🇸Altus Research - Hunt - PPDS, Lake Worth, Florida, United States
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive
- Conditions
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 651
- Registration Number
- NCT04528719
- Locations
- 🇺🇸
Velocity Clinical Research - Medford - ERN - PPDS, Medford, Oregon, United States
🇺🇸Flourish Research - San Antonio - PPDS, San Antonio, Texas, United States
🇺🇸DM Clinical Research, Tomball, Texas, United States
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 30415
- Registration Number
- NCT04470427
- Locations
- 🇺🇸
Synexus - Optimal Research - Rockville, Rockville, Maryland, United States
🇺🇸UCLA Vine Street Clinic CRS, Los Angeles, California, United States
🇺🇸VA Greater Los Angeles Healthcare (veterans only), Los Angeles, California, United States
Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 660
- Registration Number
- NCT04405076
- Locations
- 🇺🇸
Trial Management Associates, Wilmington, North Carolina, United States
🇺🇸Meridian Clinical Research, Dakota Dunes, South Dakota, United States
🇺🇸Benchmark Research, San Angelo, Texas, United States
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 315
- Registration Number
- NCT04232280
- Locations
- 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
🇺🇸Optimal Research, Peoria, Illinois, United States
🇺🇸Crossroads Clinical Research, Victoria, Texas, United States
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT04159103
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Johns Hopkins Hospital, Adult Outpatient Clinical Research Unit, Baltimore, Maryland, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
- Conditions
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT04144348
- Locations
- 🇺🇸
Child Healthcare Associates, Liverpool, New York, United States
🇺🇸Ohio Pediatric Research Assn Inc, Dayton, Ohio, United States
🇺🇸UHS Primary Care, Binghamton, New York, United States
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04064905
- Locations
- 🇵🇷
Ponce School of Medicine - CAIMED Center, Ponce, Puerto Rico
🇺🇸Benchmark Research, Fort Worth, Texas, United States
🇺🇸Meridan Clinical Research, Omaha, Nebraska, United States
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 267
- Registration Number
- NCT03897881
- Locations
- 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
🇦🇺Affinity Clinical Research, Murdoch, Western Australia, Australia
🇺🇸UPMC Hillman Cancer Center, Chicago, Illinois, United States